Patent Number: 6,166,090

Title: Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells

Abstract: TGF-beta activators and TGF-beta production stimulators are employed to maintain or increase vessel lumen diameter in a diseased or injured vessel of a mammal. Conditions such as restenosis following angioplasty, vascular bypass grafts, transplanted organs, atherosclerosis or hypertension are characterized by a reduced vessel lumen diameter. In a preferred embodiment of the invention, TGF-beta activators and production stimulators inhibit abnormal proliferation of smooth muscle cells. TGF-beta activators or production stimulators that are not characterized by an undesirable systemic toxicity profile at a prophylactic dose are also amenable to chronic use for prophylactic purposes with respect to disease states involving proliferation and/or migration of vascular smooth muscle cells over time. Further provided is a method for determining TGF-beta in vitro, thereby identifying a patient at risk for atherosclerosis and monitoring a recipient that has received one or more administrations of a TGF-beta activator or production stimulator.

Inventors: Grainger; David J. (Cambridge, GB), Metcalfe; James C. (Cambridge, GB), Weissberg; Peter L. (Cambridge, GB)

Assignee: NeoRx Corporation

International Classification: A61K 31/135 (20060101); A61K 31/00 (20060101); A61K 31/138 (20060101); A61K 31/40 (20060101); C07K 14/435 (20060101); C07K 16/22 (20060101); C07K 14/71 (20060101); C07K 16/18 (20060101); A61K 031/135 ()

Expiration Date: 12/26/2017